Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients

American Journal of Hypertension

Volumn 10, Issue 6, 1997, Pages 600-610

  Masuo, Kazuko ^a   Mikami, Hiroshi ^a   Ogihara, Toshio ^a   Tuck, Michael L ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Captopril; Glucose metabolism; Hypertension; Lipid metabolism; Nifedipine retard

Indexed keywords

CAPTOPRIL; NIFEDIPINE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE RATE;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CALCIUM CHANNEL BLOCKERS; CAPTOPRIL; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; NIFEDIPINE; TIME FACTORS;

EID: 0030848063     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00047-2     Document Type: Article

References (38)

1. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med. 317:1987;350-357.
2. Lucas CP, Estigrribia JA, Darga LL, Reaven GM. Insulin and blood pressure in obesity. Hypertension. 7:1985;702-706.
3. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest. 75:1985;805-817.
4. Bühler FR, Julius S, Reaven GM. A new dimension in hypertension: role of insulin resistance. J Cardiovascular Pharmacol. 1:((suppl 5)):1990;S1-S3.
5. Sowers JR. Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension and accelerated atherosclerosis. J Clin Pharmacol. 32:1992;529-535.
6. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J. 121:1991;1283-1288.
7. Davidson MB. Clinical implications of insulin resistance syndrome. Am J Medicine. 99:1995;420-426.
8. Julius S, Jamerson K, Mejia A, et al. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study. JAMA. 264:1990;354-359.
9. Kaplan NM. Effects on antihypertensive therapy on insulin resistance. Hypertension. 19:((suppl I)):1992;I-116-I-118.
10. Santoro D, Natali A, Galvan AQ, et al. Glucose tolerance and insulin secretion in essential hypertension after treatment with an angiotensin converting enzyme inhibitor. J Hypertens. 9:((suppl 6)):1991;S406-S407.
11. Paolliso G, Gambardella A, Verza M, et al. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Human Hypertension. 6:1992;175-179.
12. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 321:1989;868-873.
13. Donnelly R. Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol. 20:((suppl 11)):1992;S38-S44.
14. Santcci A, Ferri C. Insulin resistance and essential hypertension: pathophysiologic and therapeutic implications. J Hypertens. 10:((suppl 2)):1992;S9-S15.
15. Ishimitsu T, Yagi S, Sugishita Y, et al. Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Hypertens Res. 19:1996;43-49.
16. Torlone E, Renbatti AM, Perriello G, et al. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type-2 (non-insulin dependent) diabetes mellitus and arterial hypertension. Diabetologica. 34:1991;119-125.
17. Pollare T, Lithell H, Morlin C, et al. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens. 7:1989;551-559.
18. Tentoria A, Ghilardi G, Pedroncelli A, et al. Insulin secretion and glucose tolerance in non-insulin dependent diabetic patients after chronic nifedipine treatment. Eur J Clin Pharmacol. 36:1989;311-313.
19. Chellingsworth M, Kendall M, Wright A, et al. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. J Human Hypertension. 3:1989;35-39.
20. Trost BN, Weidmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens. 5:1987;S81-S104.
21. Schoen RE, Frishman WH, Shamoon H. Hormonal and metabolic effects of calcium channel antagonists in man. Am J Med. 84:1988;492-504.
22. Ramsay LE, Yeo WW, Jackson PR. Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose tolerance in hypertensive patients. J Cardiovascular Pharmacol. 20:((suppl II)):1992;S49-S54.
23. Suter PM, Vetter W. Metabolic effects of antihypertensive drugs. J Hypertension. 13:((suppl 4)):1995;S11-S17.
24. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristics feature of primary hypertension independently of obesity. Metabolism. 39:1990;167-174.
25. Sowers JR, Standley PR, Ram JL, et al. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens. 6:1993;260S-270S.
26. Christlieb AR, Krolewski AS, Warram JH, Soeldner JS. Is insulin the link between hypertension and obesity? Hypertension. 7:((suppl II)):1985;II-54-II-57.
27. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens. 13:1995;1457-1462.
28. Esler MD, Jennings GL, Korner P, et al. Assessment of human sympathetic nervous system activity from measurements of noradrenaline turnover. Hypertension. 11:1988;3-20.
29. Esler MD, Lambert G, Jennings GL. Increased regional sympathetic nerve activity in human hypertension: causes and consequences. J Hypertens. 8:((suppl 7)):1990;S53-S57.
30. Ferrier C, Esler MD, Eisenhofer G, et al. Increased norepinephrine spillover into the jugular vein in essential hypertension. Hypertension. 19:1992;62-69.
31. Anderson EA, Balon TW, Hoffman RP, et al. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension. 19:1992;621-627.
32. Radaelli A, Bernardi L, Valle F, et al. Cardiovascular autonomic modulation in essential hypertension. Effect of tilting. Hypertension. 24:1994;556-563.
33. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man; a novel mechanism for insulin resistance. J Clin Invest. 85:1990;1844-1852.
34. Coste SC, Qi Y, Brooks VL, et al. Captopril and stress-induced hypertension in the borderline hypertensive rat. J Hypertens. 13:1995;1391-1398.
35. Leighton B, Chaliss RAJ, Newsholme EA. The role of prostaglandins as modulators of insulin-stimulated glucose metabolism in skeletal muscle. Horm Metab Res. 22:1990;89-95.
36. Hartl WH, Jauch KW, Wolfe RR, Schildberg FW. Effects of kinins on glucose metabolism in vivo. Horm Metab Res. 22:1990;79-84.
37. Dessi-Fulgheri P, Espinosa E, Zingaretti O, et al. Urinary kallikrein excretion and blood pressure response to angiotensin converting enzyme inhibitors and calcium antagonists in hypertensive patients. J Hypertens. 11:1993;725-730.
38. Tobey TA, Greenfield M, Kraemer F, Reaven GM. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normotriglyceridemia man. Metabolism. 30:1981;165-171.